Novan, Inc. (NOVN): Price and Financial Metrics


Novan, Inc. (NOVN): $1.40

-0.02 (-1.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NOVN POWR Grades

  • NOVN scores best on the Sentiment dimension, with a Sentiment rank ahead of 91.02% of US stocks.
  • NOVN's strongest trending metric is Value; it's been moving up over the last 177 days.
  • NOVN's current lowest rank is in the Quality metric (where it is better than 2.21% of US stocks).

NOVN Stock Summary

  • NOVN has a market capitalization of $34,247,119 -- more than approximately merely 10.23% of US stocks.
  • Revenue growth over the past 12 months for NOVAN INC comes in at 310.91%, a number that bests 96.9% of the US stocks we're tracking.
  • The volatility of NOVAN INC's share price is greater than that of 89.59% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NOVAN INC are CRNT, SIGA, NURO, KMDA, and WPRT.
  • NOVN's SEC filings can be seen here. And to visit NOVAN INC's official web site, go to www.novan.com.

NOVN Valuation Summary

  • In comparison to the median Healthcare stock, NOVN's price/sales ratio is 7.32% higher, now standing at 2.2.
  • NOVN's price/sales ratio has moved NA NA over the prior 77 months.

Below are key valuation metrics over time for NOVN.

Stock Date P/S P/B P/E EV/EBIT
NOVN 2023-01-20 2.2 4.5 -0.8 -0.5
NOVN 2023-01-19 2.1 4.2 -0.8 -0.5
NOVN 2023-01-18 2.3 4.6 -0.9 -0.6
NOVN 2023-01-17 2.3 4.7 -0.9 -0.6
NOVN 2023-01-13 2.3 4.7 -0.9 -0.6
NOVN 2023-01-12 2.3 4.7 -0.9 -0.6

NOVN Growth Metrics

    Its 5 year price growth rate is now at -93.03%.
  • Its 5 year net income to common stockholders growth rate is now at 50.55%.
  • Its 4 year cash and equivalents growth rate is now at -36.49%.
NOVN's revenue has moved up $11,178,000 over the prior 52 months.

The table below shows NOVN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 13.856 -28.515 -36.521
2022-06-30 9.478 -24.132 -36.975
2022-03-31 4.067 -15.41 -34.12
2021-12-31 2.958 -24.777 -29.692
2021-09-30 3.372 -25.228 -28.094
2021-06-30 3.952 -28.259 -30.015

NOVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NOVN has a Quality Grade of D, ranking ahead of 5.71% of graded US stocks.
  • NOVN's asset turnover comes in at 0.072 -- ranking 285th of 682 Pharmaceutical Products stocks.
  • VBIV, RIOT, and ASRT are the stocks whose asset turnover ratios are most correlated with NOVN.

The table below shows NOVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 1 -8.838
2021-03-31 0.097 1 -7.579
2020-12-31 0.111 1 -7.267
2020-09-30 0.132 1 -3.706
2020-06-30 0.140 1 -2.821
2020-03-31 0.134 1 -5.195

NOVN Price Target

For more insight on analysts targets of NOVN, see our NOVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.00 Average Broker Recommendation 1.5 (Moderate Buy)

NOVN Stock Price Chart Interactive Chart >

Price chart for NOVN

NOVN Price/Volume Stats

Current price $1.40 52-week high $4.36
Prev. close $1.42 52-week low $0.79
Day low $1.35 Volume 97,800
Day high $1.46 Avg. volume 341,700
50-day MA $1.23 Dividend yield N/A
200-day MA $2.04 Market Cap 29.79M

Novan, Inc. (NOVN) Company Bio


Novan, Inc. focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company was founded in 2006 and is based in Durham, North Carolina.


NOVN Latest News Stream


Event/Time News Detail
Loading, please wait...

NOVN Latest Social Stream


Loading social stream, please wait...

View Full NOVN Social Stream

Latest NOVN News From Around the Web

Below are the latest news stories about NOVAN INC that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Novan to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday, January 19th at 12:00 PM ETDURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 12:00 PM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan

Yahoo | January 18, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

Yahoo | January 11, 2023

Novan seeks FDA approval for lead product

After years of ups and downs, Novan is seeking federal approval for its lead product to treat a viral skin infection.

Yahoo | January 9, 2023

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, most of them children1,2 – – Berdazimer gel, 10.3% has the potential to be the first FDA-approved prescription product for the treatment of molluscum3 – DURHAM, N.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), announce

Yahoo | January 6, 2023

Novan secures $5M through license deal with Japanese pharma

In addition to the upfront payment, there is also the potential for a $2.5 million milestone payment.

Yahoo | January 4, 2023

Read More 'NOVN' Stories Here

NOVN Price Returns

1-mo 9.95%
3-mo 14.75%
6-mo -51.89%
1-year -53.64%
3-year -78.84%
5-year -96.05%
YTD -4.11%
2022 -64.99%
2021 -48.71%
2020 -74.27%
2019 280.72%
2018 -80.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7619 seconds.